BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30246456)

  • 1. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.
    Huang CS; Tang SJ; Lee MH; Chang Wang CC; Sun GH; Sun KH
    J Cell Mol Med; 2018 Dec; 22(12):5909-5918. PubMed ID: 30246456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma.
    Sun KH; Sun GH; Wu YC; Ko BJ; Hsu HT; Wu ST
    J Cell Mol Med; 2016 Nov; 20(11):2020-2028. PubMed ID: 27297979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
    Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
    J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin.
    Chung LY; Tang SJ; Wu YC; Sun GH; Liu HY; Sun KH
    Oncotarget; 2015 Mar; 6(7):4936-52. PubMed ID: 25669973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
    Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
    Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties.
    Lichner Z; Saleh C; Subramaniam V; Seivwright A; Prud'homme GJ; Yousef GM
    Oncotarget; 2015 Mar; 6(8):5567-81. PubMed ID: 25011053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spheres derived from the human SN12C renal cell carcinoma cell line are enriched in tumor initiating cells.
    Zhang Y; Sun B; Zhao X; Sun H; Cui W; Liu Z; Yao X; Dong X
    J Exp Clin Cancer Res; 2016 Oct; 35(1):163. PubMed ID: 27756344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.
    Wei R; He D; Zhang X
    Cell Physiol Biochem; 2018; 49(6):2348-2357. PubMed ID: 30261494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells.
    Zhong Y; Guan K; Guo S; Zhou C; Wang D; Ma W; Zhang Y; Li C; Zhang S
    Cancer Lett; 2010 Dec; 299(2):150-60. PubMed ID: 20846785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
    Wang L; Park P; La Marca F; Than KD; Lin CY
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100B Mediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53.
    Yang T; Cheng J; Yang Y; Qi W; Zhao Y; Long H; Xie R; Zhu B
    Stem Cells; 2017 Feb; 35(2):325-336. PubMed ID: 27501952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription factor Six2 induces a stem cell-like phenotype in renal cell carcinoma cells.
    Cheng N; Li H; Han Y; Sun S
    FEBS Open Bio; 2019 Oct; 9(10):1808-1816. PubMed ID: 31420918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.
    Khan MI; Czarnecka AM; Lewicki S; Helbrecht I; Brodaczewska K; Koch I; Zdanowski R; Król M; Szczylik C
    PLoS One; 2016; 11(11):e0165718. PubMed ID: 27812180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.
    Ueda K; Ogasawara S; Akiba J; Nakayama M; Todoroki K; Ueda K; Sanada S; Suekane S; Noguchi M; Matsuoka K; Yano H
    PLoS One; 2013; 8(10):e75463. PubMed ID: 24116047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR2/Snail-1-Induced Epithelial-Mesenchymal Transition in the Formation and Progression of RCC with Inferior Vena Cava Tumour Thrombus.
    Wang L; Gao J; Zheng S; Luo Z; Xu Z; Che H; Wang Z
    Arch Esp Urol; 2024 Apr; 77(3):292-302. PubMed ID: 38715171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas.
    Rasti A; Mehrazma M; Madjd Z; Abolhasani M; Saeednejad Zanjani L; Asgari M
    Sci Rep; 2018 Aug; 8(1):11739. PubMed ID: 30082842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.
    White NM; Masui O; Newsted D; Scorilas A; Romaschin AD; Bjarnason GA; Siu KW; Yousef GM
    Br J Cancer; 2014 Mar; 110(5):1250-9. PubMed ID: 24496460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
    Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
    J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.